156 related articles for article (PubMed ID: 12203417)
1. Remodeling of gp41-C34 peptide leads to highly effective inhibitors of the fusion of HIV-1 with target cells.
Otaka A; Nakamura M; Nameki D; Kodama E; Uchiyama S; Nakamura S; Nakano H; Tamamura H; Kobayashi Y; Matsuoka M; Fujii N
Angew Chem Int Ed Engl; 2002 Aug; 41(16):2937-40. PubMed ID: 12203417
[No Abstract] [Full Text] [Related]
2. Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV.
Gustchina E; Hummer G; Bewley CA; Clore GM
J Med Chem; 2005 Apr; 48(8):3036-44. PubMed ID: 15828842
[TBL] [Abstract][Full Text] [Related]
3. A synthetic C34 trimer of HIV-1 gp41 shows significant increase in inhibition potency.
Nomura W; Hashimoto C; Ohya A; Miyauchi K; Urano E; Tanaka T; Narumi T; Nakahara T; Komano JA; Yamamoto N; Tamamura H
ChemMedChem; 2012 Feb; 7(2):205-8. PubMed ID: 22247043
[No Abstract] [Full Text] [Related]
4. Blocking HIV entry.
Buzko OV; Shokat KM
Nat Struct Biol; 1999 Oct; 6(10):906-8. PubMed ID: 10504719
[TBL] [Abstract][Full Text] [Related]
5. Chemoenzymatic synthesis of HIV-1 gp41 glycopeptides: effects of glycosylation on the anti-HIV activity and alpha-helix bundle-forming ability of peptide C34.
Wang LX; Song H; Liu S; Lu H; Jiang S; Ni J; Li H
Chembiochem; 2005 Jun; 6(6):1068-74. PubMed ID: 15883971
[TBL] [Abstract][Full Text] [Related]
6. Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor.
Deng Y; Zheng Q; Ketas TJ; Moore JP; Lu M
Biochemistry; 2007 Apr; 46(14):4360-9. PubMed ID: 17371053
[TBL] [Abstract][Full Text] [Related]
7. Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1.
Debnath AK; Radigan L; Jiang S
J Med Chem; 1999 Aug; 42(17):3203-9. PubMed ID: 10464007
[TBL] [Abstract][Full Text] [Related]
8. Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions.
Nameki D; Kodama E; Ikeuchi M; Mabuchi N; Otaka A; Tamamura H; Ohno M; Fujii N; Matsuoka M
J Virol; 2005 Jan; 79(2):764-70. PubMed ID: 15613304
[TBL] [Abstract][Full Text] [Related]
9. Development of HIV entry inhibitors targeted to the coiled-coil regions of gp41.
Jiang S; Debnath AK
Biochem Biophys Res Commun; 2000 Mar; 269(3):641-6. PubMed ID: 10720469
[TBL] [Abstract][Full Text] [Related]
10. Design of highly potent HIV fusion inhibitors based on artificial peptide sequences.
Shi W; Cai L; Lu L; Wang C; Wang K; Xu L; Zhang S; Han H; Jiang X; Zheng B; Jiang S; Liu K
Chem Commun (Camb); 2012 Dec; 48(94):11579-81. PubMed ID: 23093045
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 fusion mechanism could be target for new drugs.
Morris K
Lancet; 1997 Apr; 349(9060):1227. PubMed ID: 9130955
[No Abstract] [Full Text] [Related]
12. Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements.
Ferrer M; Kapoor TM; Strassmaier T; Weissenhorn W; Skehel JJ; Oprian D; Schreiber SL; Wiley DC; Harrison SC
Nat Struct Biol; 1999 Oct; 6(10):953-60. PubMed ID: 10504731
[TBL] [Abstract][Full Text] [Related]
13. Effect of amino acid replacements, additions and deletions on the antiviral activity of a peptide derived from the HIV-1 GP41 sequence.
Jiang S; Lin K
Pept Res; 1995; 8(6):345-8. PubMed ID: 8838418
[TBL] [Abstract][Full Text] [Related]
14. Site-specific PEGylation of HR2 peptides: effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation.
Danial M; van Dulmen TH; Aleksandrowicz J; Pötgens AJ; Klok HA
Bioconjug Chem; 2012 Aug; 23(8):1648-60. PubMed ID: 22770564
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 gp41: mediator of fusion and target for inhibition.
Weiss CD
AIDS Rev; 2003; 5(4):214-21. PubMed ID: 15012000
[TBL] [Abstract][Full Text] [Related]
16. Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.
Münch J; Ständker L; Adermann K; Schulz A; Schindler M; Chinnadurai R; Pöhlmann S; Chaipan C; Biet T; Peters T; Meyer B; Wilhelm D; Lu H; Jing W; Jiang S; Forssmann WG; Kirchhoff F
Cell; 2007 Apr; 129(2):263-75. PubMed ID: 17448989
[TBL] [Abstract][Full Text] [Related]
17. Stronger anti-HIV-1 activity of C-peptide derived from HIV-1 89.6 gp41 C-terminal heptad repeated sequence.
Seo JK; Kim HK; Lee TY; Hahm KS; Kim KL; Lee MK
Peptides; 2005 Nov; 26(11):2175-81. PubMed ID: 15876473
[TBL] [Abstract][Full Text] [Related]
18. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target.
Chan DC; Chutkowski CT; Kim PS
Proc Natl Acad Sci U S A; 1998 Dec; 95(26):15613-7. PubMed ID: 9861018
[TBL] [Abstract][Full Text] [Related]
19. The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors.
Gallo SA; Sackett K; Rawat SS; Shai Y; Blumenthal R
J Mol Biol; 2004 Jun; 340(1):9-14. PubMed ID: 15184018
[TBL] [Abstract][Full Text] [Related]
20. Non-peptide entry inhibitors of HIV-1 that target the gp41 coiled coil pocket.
Stewart KD; Huth JR; Ng TI; McDaniel K; Hutchinson RN; Stoll VS; Mendoza RR; Matayoshi ED; Carrick R; Mo H; Severin J; Walter K; Richardson PL; Barrett LW; Meadows R; Anderson S; Kohlbrenner W; Maring C; Kempf DJ; Molla A; Olejniczak ET
Bioorg Med Chem Lett; 2010 Jan; 20(2):612-7. PubMed ID: 20004576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
